FDA tumor marker 510(k) guidance to be modified to clarify circumstances requiring clinical data.
This article was originally published in The Gray Sheet
Executive Summary
FDA TUMOR MARKER 510(k) GUIDANCE TO BE MODIFIED by the agency with input from industry and FDA's Immunology Devices Panel. Issues to be addressed in the modification process include the circumstances under which clinical data should be provided for 510(k) applications.